Article
Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab.
Molecular cancer - 4 Jun 2014
Cho Jeonghee, Bass Adam J, Lawrence Michael S, Cibulskis Kristian, Cho Ahye, Lee Shi-Nai, Yamauchi Mai, Wagle Nikhil, Pochanard Panisa, Kim Nayoung, Park Angela Kj, Won Jonghwa, Hur Hyung-Suk, Greulich Heidi, Ogino Shuji, Sougnez Carrie, Voet Douglas, Tabernero Josep, Jimenez Jose, Baselga Jose, Gabriel Stacey B, Lander Eric S, Getz Gad, Eck Michael J, Park Woong-Yang, Meyerson Matthew
Abstract excerpt
BACKGROUND: Inhibition of the activated epidermal growth factor receptor (EGFR) with either enzymatic kinase inhibitors or anti-EGFR antibodies such as cetuximab, is an effective modality of treatment for multiple human cancers. Enzymatic EGFR inhibitors are effective for lung adenocarcinomas with somatic kinase domain EGFR mutations while, paradoxically, anti-EGFR antibodies are more effective in colon and head...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.